Subscribe

Medicure Inc. (MPH.V)

CAD1.07 +0.00 (+0.00%)
CA TSXV Healthcare Drug Manufacturers - Specialty & Generic
Address 2-1250 Waverley Street R3T 6C6
Winnipeg, MB, CA
CEO Albert David Friesen
Website medicure.com
IPO 2012-09-06
ISIN CA58469E4085

Explore sections of this company profile

Also trades on Other OTC · MCUJF (USD) Toronto Stock Exchange Ventures · MPH.V (CAD)
Description

Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CAD1.07 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.8K
Beta
1.06
Float Shares
7.59M
Free Float %
72.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% +22.22% -1.79% +0.00% -3.51% +17.02% +0.00% -8.33% -79.32% +83.33%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.07
DCF (Unlevered) 2.21 +106.5%
DCF (Levered) 5.38 +402.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2024-11 Change
Strong Buy 1 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-3.39
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +31.7% ★ Q1'26: +44.9% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -582.7% Q1'26: +41.5% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -4.8% Q1'26: -23.0% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -23.9% Q1'26: -4.6% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -69.1% Q1'26: -12.3% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.0% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -0.21× Q1'26: 0.72× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.97) × ERP
WACC = 93% × Ke + 7% × Kd (4.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 2.24 Current price: 1.07
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2031
1 Rev. Ana.
1 EPS Ana. 		Dec 2032
1 Rev. Ana.
1 EPS Ana.
Revenue
22.08M
est: 21.84M (+1.1%)
37.78M
est: 34.12M (+10.7%)
27.13M
est: 43.94M (-38.3%)
29.11M
est: 29.26M (-0.5%)
20.17M
est: 23.89M (-15.6%)
11.61M
est: 20.16M (-42.4%)
21.74M
est: 22.73M (-4.3%)
23.07M
est: 23.40M (-1.4%)
21.69M
est: 20.44M (+6.1%)
21.91M
est: 20.44M (+7.2%)
28.86M
est: 43.94M (-34.3%)
43.94M
43.94M – 43.94M
+0.0% YoY
29.26M
29.26M – 29.26M
-33.4% YoY
23.89M
23.89M – 23.89M
-18.3% YoY
20.16M
20.16M – 20.16M
-15.6% YoY
22.73M
22.73M – 22.73M
+12.7% YoY
23.40M
23.40M – 23.40M
+2.9% YoY
20.44M
20.44M – 20.44M
-12.6% YoY
EBITDA
2.35M
est: 172.5K (+1,261.2%)
5.44M
est: 269.4K (+1,917.7%)
2.62M
est: 347.0K (+656.3%)
5.15M
est: 231.1K (+2,127.0%)
-17.72M
est: 188.7K (-9,488.5%)
-4.05M
est: 159.3K (-2,640.0%)
2.39M
est: 179.5K (+1,229.0%)
3.44M
est: 184.8K (+1,761.6%)
1.27M
est: 161.4K (+688.6%)
1.54M
est: 984.7K (+56.5%)
-4.24M
est: 2.12M (-300.4%)
2.12M
2.12M – 2.12M
+0.0% YoY
1.41M
1.41M – 1.41M
-33.4% YoY
1.15M
1.15M – 1.15M
-18.3% YoY
971.4K
971.4K – 971.4K
-15.6% YoY
1.10M
1.10M – 1.10M
+12.7% YoY
1.13M
1.13M – 1.13M
+2.9% YoY
984.7K
984.7K – 984.7K
-12.6% YoY
EBIT
1.66M
est: -2.79M (+159.4%)
4.00M
est: -4.36M (+191.9%)
2.53M
est: -5.61M (+145.0%)
4.82M
est: -3.74M (+229.1%)
-19.62M
est: -3.05M (-542.7%)
-6.80M
est: -2.58M (-163.8%)
-721.0K
est: -2.90M (+75.2%)
1.36M
est: -2.99M (+145.6%)
-897.0K
est: -2.61M (+65.6%)
-773.0K
est: -1.19M (+34.8%)
-6.89M
est: -2.55M (-170.1%)
-2.55M
-2.55M – -2.55M
+0.0% YoY
-1.70M
-1.70M – -1.70M
+33.4% YoY
-1.39M
-1.39M – -1.39M
+18.3% YoY
-1.17M
-1.17M – -1.17M
+15.6% YoY
-1.32M
-1.32M – -1.32M
-12.7% YoY
-1.36M
-1.36M – -1.36M
-2.9% YoY
-1.19M
-1.19M – -1.19M
+12.6% YoY
Net Income
1.67M
est: 2.85M (-41.5%)
27.66M
est: 3.30M (+736.9%)
43.42M
est: -4.17M (+1,140.1%)
3.93M
est: 2.19M (+79.1%)
-19.79M
est: -3.03M (-553.8%)
-6.85M
est: -3.13M (-118.6%)
-727.0K
est: -3.24M (+77.5%)
1.37M
est: -2.82M (+148.4%)
-922.0K
est: -3.76M (+75.5%)
-1.04M
est: -3.76M (+72.3%)
-7.10M
est: -4.17M (-70.0%)
-4.17M
-4.17M – -4.17M
+0.0% YoY
2.19M
2.19M – 2.19M
+152.5% YoY
-3.03M
-3.03M – -3.03M
-238.1% YoY
-3.13M
-3.13M – -3.13M
-3.4% YoY
-3.24M
-3.24M – -3.24M
-3.3% YoY
-2.82M
-2.82M – -2.82M
+12.9% YoY
-3.76M
-3.76M – -3.76M
-33.3% YoY
SGA
10.24M
est: 13.69M (-25.2%)
16.23M
est: 21.39M (-24.1%)
14.87M
est: 27.55M (-46.0%)
19.50M
est: 18.34M (+6.3%)
16.79M
est: 14.98M (+12.1%)
9.94M
est: 12.64M (-21.4%)
13.01M
est: 14.25M (-8.7%)
12.13M
est: 14.67M (-17.3%)
12.44M
est: 12.82M (-3.0%)
12.75M
est: 11.44M (+11.4%)
14.96M
est: 24.59M (-39.1%)
24.59M
24.59M – 24.59M
+0.0% YoY
16.37M
16.37M – 16.37M
-33.4% YoY
13.37M
13.37M – 13.37M
-18.3% YoY
11.28M
11.28M – 11.28M
-15.6% YoY
12.72M
12.72M – 12.72M
+12.7% YoY
13.09M
13.09M – 13.09M
+2.9% YoY
11.44M
11.44M – 11.44M
-12.6% YoY
EPS
0.12
est: 0.27 (-56.1%)
1.80
est: 0.32 (+468.4%)
2.78
est: -0.40 (+795.0%)
0.25
est: 0.21 (+19.0%)
-1.32
est: -0.29 (-355.2%)
-0.64
est: -0.30 (-113.3%)
-0.07
est: -0.31 (+77.1%)
0.13
est: -0.27 (+148.1%)
-0.09
est: -0.36 (+75.0%)
-0.10
est: -0.36 (+72.3%)
-0.68
est: -0.40 (-70.0%)
-0.40
-0.40 – -0.40
+0.0% YoY
0.21
0.21 – 0.21
+152.5% YoY
-0.29
-0.29 – -0.29
-238.1% YoY
-0.30
-0.30 – -0.30
-3.4% YoY
-0.31
-0.31 – -0.31
-3.3% YoY
-0.27
-0.27 – -0.27
+12.9% YoY
-0.36
-0.36 – -0.36
-33.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-21 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-20 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-19 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-14 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-13 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-12 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-11 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-07 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-05 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-04 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-01 B- 2/5 5/5 1/5 1/5 2/5 1/5 4/5
2026-04-30 B- 2/5 5/5 1/5 1/5 2/5 1/5 4/5
2026-04-28 B- 2/5 5/5 1/5 1/5 2/5 1/5 4/5
2026-04-27 B- 2/5 5/5 1/5 1/5 2/5 1/5 4/5
2026-04-24 B- 2/5 5/5 1/5 1/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-2.50M
OE per share TTM
-0.24
Owner's Yield
-21.79%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-275.5K
Shares Outstanding
10.44M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Albert David Friesen Founder, CEO, President & Chairman of the Board 264.0K —
Neil Owens President & Chief Operating Officer 236.5K —
Haaris Uddin Chief Financial Officer 172.0K male
Reuben Saba Vice President of Scientific & Medical Affairs 165.0K —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic